Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Paul Jeng initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $35.
Guggenheim analyst Paul Jeng initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $35.